v3.25.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended June 30,Six Months Ended June 30,
Revenue by product (in thousands) 2025202420252024
MACI implants, kits, and instruments
Implants based on contracted rate sold through a specialty pharmacy (a)
$39,430 $30,704 $71,471 $58,083 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
2,688 3,332 5,371 6,529 
Implants sold direct based on contracted rates (c)
8,903 8,099 17,325 14,501 
Implants sold direct subject to third-party reimbursement (d)
991 965 2,615 2,150 
Biopsy kits and instruments - direct bill642 492 1,238 1,058 
Change in estimates related to prior periods (e)
804 543 1,735 1,995 
Total MACI implants, kits, and instruments53,458 44,135 99,755 84,316 
Epicel
Direct bill (hospital)8,614 7,758 13,578 18,422 
NexoBrid1,168 769 2,505 1,205 
Total revenue$63,240 $52,662 $115,838 $103,943 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.